Quality of Life in Older Patients after a Heart Failure Hospitalization: Results from the SENECOR Study

Daniele Luiso 1,2, Marta Herrero-Torrus 3, Neus Badosa 1,4, Cristina Roqueta 2,3, Sonia Ruiz-Bustillo 1,4,5, Laia C. Belarte-Tornero 1,4, Sandra Valdivielso-More 1,4, Ronald O. Morales 1, Olga Vázquez 3 and Núria Farré 1,2,4,*

1 Heart Failure Unit, Cardiology Department, Hospital del Mar, 08003 Barcelona, Spain; d.luiso@gmail.com (D.L.); nbadosa@psmar.cat (N.B.); sruiz@psmar.cat (S.R.-B.); lblarte@psmar.cat (L.C.B.-T.); svaldivielso@psmar.cat (S.V.-M.); romoralesmurillo@psmar.cat (R.O.M.)
2 Department of Medicine, Universitat Autònoma de Barcelona, 08193 Barcelona, Spain; croqueta@psmar.cat
3 Geriatrics Department, Hospital del Mar, 08003 Barcelona, Spain; mherrero@psmar.cat (M.H.-T.);
ovazquez@psmar.cat (O.V.)
4 Biomedical Research Group on Heart Disease, Hospital del Mar Medical Research Group (IMIM), 08003 Barcelona, Spain
5 Department of Medicine, Universidad Pompeu Fabra, 08022 Barcelona, Spain
* Correspondence: nfarrelopez@psmar.cat

Abstract: Background: Information about health-related quality of life (HRQoL) in heart failure (HF) in older adults is scarce. Methods: We aimed to describe the HRQoL of the SENECOR study cohort, a single-center, randomized trial comparing the effects of multidisciplinary intervention by a geriatrician and a cardiologist (intervention group) to that of a cardiologist alone (control group) in older patients with a recent HF hospitalization. Results: HRQoL was assessed by the short version of the disease-specific Kansas Cardiomyopathy Questionnaire (KCCQ-12) in 141 patients at baseline and was impaired (KCCQ-12 < 75) in almost half of the cohort. Women comprised 50% of the population, the mean age was 82.2 years, and two-thirds of patients had preserved ejection fraction. Comorbidities were highly prevalent. Patients with impaired HRQoL had a worse NYHA functional class, a lower NT-proBNP, a lower Barthel index, and a higher Clinical Frailty Scale. One-year all-cause mortality was 22.7%, significantly lower in the group with good-to-excellent HRQoL (14.5% vs. 30.6%; hazard ratio 0.28; 95% confidence interval 0.10–0.78; p = 0.014). In the group with better HRQoL, all-cause hospitalization was lower, and there was a trend towards lower HF hospitalization. Conclusions: The KCCQ-12 questionnaire can provide inexpensive prognostic information even in older patients with HF. (Funded by grant Primitivo de la Vega, Fundación MAPFRE. ClinicalTrials number, NCT03555318).

Keywords: quality of life; heart failure; older patients; prognosis

1. Introduction

Heart failure (HF) is one of Western society’s major public health problems. The epidemiological dimension of HF, its clinical complexity, the impact on patients’ quality of life, and the burden it represents for a health system with finite resources [1] make this syndrome one of the greatest health, organizational, and economic challenges of the present day.

The clinical practice guidelines of the European Society of Cardiology [2] establish that the main goals of the treatment of patients with HF are to improve quality of life, reduce mortality, and reduce hospitalizations. Classically, the efficacy endpoint used to evaluate new therapies in HF is to reduce mortality. On the one hand, mortality has the advantage that it is a strong and an easy-to-measure event. On the other hand, it has an important disadvantage: being the final manifestation of the disease, it does not represent
the clinical course until the fatal outcome, or the evolution of those patients who do not die [3]. Thus, considering that HF is a chronic and progressive disease with florid symptoms and significant repercussions on functionalism, an ideal efficacy endpoint should reflect both the symptoms and the patient’s subjective perception of their health status [3–6]. In this way, assessing health-related quality of life (HRQoL) as an efficacy endpoint in HF is crucial. It provides precious information on both the patients who survive and those who die. It has been shown that HRQoL in HF correlates well with both disease severity and mortality and allows cost-effectiveness evaluations when implementing new therapeutic options [7,8]. The measurement of HRQoL is easy and inexpensive since it is carried out through questionnaires that can be generic or specific to the disease. HRQoL is a multidimensional concept that includes four fundamental aspects: physical, psychological, social, and functional status. The multidimensional nature of HRQoL allows for capturing a complete perspective of the patient. The impairment of HRQoL in HF is reflected, above all, in the functional dimension, with particular repercussions in the domains that inform about mobility and activities of daily living [9].

Information on HRQoL in HF in older adults is scarce. Most of the data reported in the literature on HRQoL in HF come from studies that include non-older patients and patients with reduced left ventricular ejection fraction (LVEF) [8,10–15]. Describing HRQoL and its correlation with prognosis in older people with HF could provide valuable clinical information, since the improvement in HRQoL in this population could have an even higher value than a reduction in mortality, both for patients and health professionals [16].

2. Materials and Methods

2.1. Study Design

The SENECOR study was a single-center, randomized trial comparing the effects of multidisciplinary intervention by a geriatrician and a cardiologist (intervention group) to that of a cardiologist alone (control group) in older patients with a recent HF hospitalization. The primary endpoint for the trial was all-cause hospitalization. Quality-of-life assessment was a pre-specified secondary endpoint of the SENECOR study. The Ethics Committee approved the study (number 2017/7653/I) and all patients signed written informed consent forms. The details of the study design and results have been published [17] and the trial is registered with ClinicalTrials.gov (NCT03555318). Briefly, patients 75 years or older and hospitalized due to HF were randomized to a follow-up performed by a cardiologist (usual care) or by a cardiologist and a geriatrician. All patients were assessed with the Canadian Study of Health and Aging (CSHA) Clinical Frailty Scale during hospitalization [18]. Frailty was defined as a CSHA equal to or higher than 4. Functional status was assessed with the Lawton and Barthel index [19] and cognitive status with the Spanish version of the Pfeiffer Questionnaire (Short Portable Mental Status Questionnaire (SPMSQ)) [20]. The 12-item Kansas City Cardiomyopathy Questionnaire (KCCQ-12) was used to assess HRQoL specifically related to HF [21]. The functional class was evaluated by the New York Heart Association (NYHA) classification. In patients randomized to the intervention group, the geriatrician assessed the social sphere with the Gijón socio-family assessment scale (abbreviated and modified) (Barcelona version) [22], the emotional sphere with the Geriatric Depression Scale Short Form (GDS-SF) Yesavage [23], nutritional status with the Mini Nutritional Assessment Short Form (MNA-SF) [24] and plasma albumin, and the presence of geriatric syndromes. After the geriatrician assessment and depending on the patient’s needs, up to eighteen interdisciplinary interventions were carried out in each area evaluated. The study showed that the multidisciplinary intervention by the cardiologist and geriatrician was associated with a decrease in all-cause hospitalization at one-year follow-up (62.7% in the intervention group and 77.3% in the control group) (hazard ratio 0.67; 95% confidence interval 0.46–0.99; \( p = 0.046 \)) [17].

In the SENECOR study, the calculated sample size to detect a statistically significant difference between the two groups was 114 patients in the intervention group and 114 patients in the control group for 1 year [17]. However, patients with exclusion criteria or who
refused to participate were higher than expected, and the estimated patient goal was not reached. On the other hand, the number of events was much higher than anticipated. Of the 150 patients who were finally included in the SENECOR study, we only included in the present study patients who had answered the KCCQ-12 at baseline, leaving a sample size of 141 patients (Figure 1).

![Flow diagram of the study.](image)

**Figure 1.** Flow diagram of the study.

### 2.2. Quality-of-Life Assessment

The KCCQ-12 is the short version (12-item) of the Kansas City Cardiomyopathy Questionnaire (KCCQ) (23-item). This self-administered test measures symptoms, physical and social limitations, and quality of life in patients with HF. It has been validated in HF both with reduced and preserved ejection fractions [8,26]. Moreover, it has proven to be both reproducible and sensitive to important changes in HF health status [26–29]. The shorter version has shown to be more feasible to implement while preserving the psychometric properties of the full instrument [22]. Scores for each domain are summarized by the KCCQ summary score, which has values between 0 and 100, with higher scores indicating better HF-specific health status. An increase of fewer than 5 points is considered a small clinical change [28]. Several studies have established a KCCQ-12 cut-off point of 75 or higher to identify patients with good-to-excellent HRQoL [30]. Therefore, we considered HRQoL impaired if KCCQ-12 was below 75. In the SENECOR study, KCCQ-12 was measured during the baseline visit. At one-year follow-up, all the baseline assessments including KCCQ-12 were repeated in those who survived.

### 2.3. Study Outcome

The main aim was to evaluate whether a good-to-excellent HRQoL was associated with lower all-cause mortality at one-year follow-up.

The secondary objectives were to evaluate whether a good-to-excellent HRQoL was associated with lower all-cause hospitalization and HF hospitalization at one-year follow-up and evaluate the extent of change in the KCCQ-12 scores at one-year follow-up.

### 2.4. Statistical Analysis

Mean and standard deviation were used to describe continuous variables, and numbers and proportions to describe the categorical variables. The chi-square test or Fisher’s exact test for categorical variables and the Student’s t-test for continuous variables were used to assess the baseline differences between patients with KCCQ-12 below and over 75.
Time-to-event data were evaluated using Kaplan–Meier estimates and Cox proportional-hazards models. The adjusted hazard ratio (HR) of HF hospitalization for HRQoL measured by the KCCQ-12 was analyzed using Cox proportional hazard models. The models were adjusted for potential confounders selected among patient characteristics that were significantly associated with a better HRQoL status. We included all variables with $p < 0.05$. We decided to include age and gender due to their known prognostic value.

Study data were collected and managed using REDCap electronic data capture tools hosted at Parc de Salut Mar [31,32]. REDCap (Research Electronic Data Capture) is a secure, web-based software platform designed to support data capture for research studies, providing (1) an intuitive interface for validated data capture; (2) audit trails for tracking data manipulation and export procedures; (3) automated export procedures for seamless data downloads to common statistical packages; and (4) procedures for data integration and interoperability with external sources.

3. Results

One hundred and fifty patients were randomized between 2 July 2018 and 15 November 2019. A total of 141 patients answered the KCCQ-12 at baseline and were included in the analysis. Figure 1 shows the flow diagram of the study.

HRQoL was impaired in almost half of the cohort. Only 2 patients (1.4%) had very-poor-to-poor HRQoL (KCCQ-12 0–24), 30 patients (21.3%) had poor-to-fair HRQoL (KCCQ-12 25–49), and 40 patients (28.4%) a fair-to-good HRQoL (KCCQ-12 50–74). A good-to-excellent HRQoL (KCCQ 75–100) was present in 48.9% of patients at the baseline visit. Women comprised 50% of the population, the mean age was 82.2 years, and two-thirds of patients had HF with a preserved ejection fraction. Comorbidities were highly prevalent. Baseline characteristics were not different between patients with impaired and non-impaired HRQoL (Table 1).

Table 1. Baseline clinical and demographic characteristics of the patients included in the study.

|                          | KCCQ < 75 ($n = 72$) | KCCQ 75–100 ($n = 69$) | p-Value |
|--------------------------|----------------------|------------------------|---------|
| Age (years)              | 81.7 ± 4.8           | 82.3 ± 4.7             | 0.43    |
| Female                   | 37 (51.4)            | 34 (49.3)              | 0.80    |
| Hypertension             | 63 (90)              | 62 (89.9)              | 0.98    |
| Diabetes mellitus        | 31 (44.3)            | 28 (41.2)              | 0.71    |
| Dyslipidemia             | 47 (66.2)            | 41 (59.4)              | 0.41    |
| Stroke/TIA               | 9 (13.4)             | 10 (15.4)              | 0.75    |
| Chronic kidney disease   | 54 (75)              | 44 (63.8)              | 0.15    |
| Anemia                   | 42 (58.3)            | 39 (56.5)              | 0.83    |
| Peripheral vascular disease | 9 (12.7)           | 14 (20.6)              | 0.21    |
| Chronic lung disease     | 28 (38.9)            | 18 (26.1)              | 0.11    |
| Cancer                   | 16 (22.5)            | 19 (27.9)              | 0.43    |
| Myocardial infarction    | 18 (25)              | 11 (15.9)              | 0.18    |
| Coronary percutaneous intervention | 14 (19.4)          | 10 (14.5)              | 0.43    |
| TAVI or Mitraclip        | 1 (1.4)              | 2 (2.9)                | 0.48    |
| Cardiac surgery:         |                      |                        |         |
| CABG                     | 2 (2.8)              | 3 (4.3)                |         |
| Valve replacement        | 4 (5.6)              | 6 (8.7)                | 0.60    |
| CABG and valve replacement | 3 (4.2)            | 2 (2.8)                |         |
| Atrial fibrillation or flutter | 54 (75)            | 43 (62.3)              | 0.10    |
| Moderate-to-severe valve disease | 22 (31.4)        | 22 (32.8)              | 0.86    |
| Device therapy:          |                      |                        |         |
| Pacemaker                | 12 (16.7)            | 10 (14.5)              | 0.52    |
| CRT or ICD               | 1 (1.4)              | 4 (5.7)                |         |
### Table 1. Cont.

| Previous history of HF | KCCQ < 75 (n = 72) | KCCQ 75–100 (n = 69) | p-Value |
|------------------------|---------------------|----------------------|---------|
| Duration of HF *:      |                     |                      |         |
| <3 months              | 12 (27.9)           | 3 (7.9)              |         |
| 3–6 months             | 1 (2.3)             | 3 (7.9)              |         |
| 6–12 months            | 4 (9.3)             | 5 (13.2)             | 0.18    |
| 1–5 years              | 17 (39.5)           | 15 (39.5)            |         |
| >5 years               | 9 (20.9)            | 11 (28.9)            |         |
| HF hospitalization the previous year * | 19 (45.2) | 12 (32.4) | 0.25 |
| HF categories:         |                     |                      |         |
| HFpEF (LVEF ≥ 50%)     | 48 (66.7)           | 46 (66.7)            |         |
| HFmrEF (LVEF 40–49%)   | 9 (12.5)            | 6 (8.7)              | 0.70    |
| HFrEF (LVEF < 40%)     | 15 (20.8)           | 17 (24.6)            |         |
| Ecocardiographic parameters: |                   |                      |         |
| LVEF (%)               | 52.1 ± 13.6         | 52.7 ± 15.2          | 0.79    |
| Left ventricular mass index (g/m²), n = 134 | 120.2 ± 30.7 | 134.2 ± 36.7 | 0.018 |
| TAPSE (mm), n = 126    | 17.5 ± 4.3          | 17.3 ± 3.6           | 0.72    |
| Right ventricle (mm), n = 88 | 28.9 ± 6.7 | 29.7 ± 7.3 | 0.56 |
| Heart failure etiology |                     |                      |         |
| Ischaemic              | 10 (14.1)           | 12 (17.4)            |         |
| Hypertensive           | 11 (15.5)           | 12 (17.4)            |         |
| Dilated cardiomyopathy | 4 (5.6)             | 6 (8.7)              | 0.16    |
| Valve heart disease    | 21 (29.6)           | 17 (24.6)            |         |
| Other/unknown          | 25 (35.2)           | 22 (31.9)            |         |
| Medications at discharge: |                   |                      |         |
| ACEI/ARB-II/ARNI       | 35 (49.3)           | 39 (57.4)            | 0.34    |
| MRA                    | 9 (12.7)            | 12 (17.6)            | 0.41    |
| Betablockers           | 52 (73.2)           | 49 (72.1)            | 0.87    |
| Diuretics              | 68 (95.8)           | 67 (98.5)            | 0.62    |
| Anticoagulation        | 53 (74.6)           | 46 (67.6)            | 0.36    |
| Antiplatelet therapy   | 12 (16.9)           | 14 (20.6)            | 0.58    |
| Oral antidiabetic drugs| 24 (34.3)           | 20 (29.4)            | 0.54    |
| Insulin                | 14 (19.7)           | 10 (14.7)            | 0.43    |
| Proton-pump inhibitors | 48 (67.6)           | 46 (67.6)            | 1.00    |
| Statin                 | 50 (70.4)           | 37 (54.4)            | 0.051   |
| Calcium channel antagonists | 25 (36.2) | 17 (25.0) | 0.15 |
| Nitrates               | 16 (22.5)           | 10 (14.7)            | 0.24    |
| Hydralazine            | 10 (14.1)           | 7 (10.3)             | 0.50    |
| Amiodarone             | 16 (22.9)           | 8 (11.8)             | 0.09    |
| Digoxin                | 3 (4.3)             | 1 (1.5)              | 0.62    |
| Vitamin D supplements  | 25 (35.2)           | 20 (29.4)            | 0.47    |
| Oral iron supplements  | 19 (26.8)           | 19 (27.9)            | 0.88    |
| Benzo diazepines       | 16 (22.5)           | 14 (20.6)            | 0.78    |
| Antidepressant drugs   | 20 (28.2)           | 16 (23.5)            | 0.53    |
| Bronchodilators        | 27 (38.0)           | 20 (29.4)            | 0.28    |

Data are numbers (percentage) or mean ± standard deviation. ACEI: angiotensin-converting enzyme inhibitors; ARB-II: angiotensin II receptor blockers; ARNI: angiotensin receptor and neprilysin inhibition; CABG: coronary artery bypass grafting; CRT: cardiac resynchronization therapy; HF: heart failure; HFrEF: heart failure with reduced ejection fraction; HFmrEF: heart failure with mildly reduced ejection fraction; HFpEF: heart failure with preserved ejection fraction; ICD: implantable cardioverter defibrillator; LVEF: left ventricular ejection fraction; MRA: mineralocorticoid receptor antagonists; TIA: transient ischemic attack; TAPSE: tricuspid annular plane systolic excursion; TAVI: transcatheter aortic valve implantation. * Only for patients with a previous history of HF.
The only statistically significant differences were a lower NYHA functional class and a surprisingly higher NT-proBNP and left ventricular mass index in the group with better HRQoL. These patients also had a higher Barthel index and a lower Clinical Frailty Scale (Table 2).

Table 2. Hospitalization and first appointment characteristics.

|                                | KCCQ < 75 (n = 72) | KCCQ 75–100 (n = 69) | p-Value |
|--------------------------------|--------------------|----------------------|---------|
| NT-proBNP at discharge, pg/mL  | 1977.5 (950.5–3917.0) | 2774.5 (1767.0–6191.5) | 0.018   |
| High-sensitivity T troponin (Hs-TnT) at discharge, ng/L | 37.5 (26.6–65.1) | 43.7 (30.5–70.2) | 0.26    |
| eGFR (mL/min) at discharge     | 46.4 ± 19.9        | 47.3 ± 20.4          | 0.81    |
| Frailty (Clinical Frailty Scale) ≥ 4 | 44 (61.1)       | 27 (40.3)            | 0.014   |
| Clinical Frailty Scale         | 4.2 ± 1.4          | 3.7 ± 1.1            | 0.02    |
| Barthel index                  | 81.8 ± 19.7        | 90.4 ± 12.3          | 0.002   |

Basic activities of daily living (Barthel index):  
- Independent (100): 17 (23.6) vs. 25 (36.2); p = 0.07  
- Minimally dependent (61–99): 45 (62.5) vs. 41 (59.4); p = 0.054  
- Partially to totally dependent (0–60): 10 (13.9) vs. 3 (4.3); p = 0.001  

Instrumental activities of daily living (Lawton index):  
- 4.6 ± 2.3 vs. 5.3 ± 1.9; p = 0.054  
- Pfeiffer Short Portable Mental Status Questionnaire (SPMSQ): 1 (1–3) vs. 1 (0–2); p = 0.08  
- NYHA functional class: 2.5 ± 0.6 vs. 2 ± 0.4; p = <0.001  
- Intervention geriatrician and cardiologist: 31 (43.1) vs. 40 (58); p = 0.08  
- KCCQ-12 at baseline: 53 ± 15.9 vs. 88.3 ± 7.8; p = <0.001

Data are number (percentage), mean ± standard deviation, or median (interquartile range). eGFR: estimated glomerular filtration rate; NT-proBNP: N-terminal prohormone of brain natriuretic peptide; NYHA: New York Heart Association; KCCQ-12: Kansas City Cardiomyopathy Questionnaire-12.

One-year all-cause mortality was 22.7% and was significantly lower in the group with good HRQoL (14.5% vs. 30.6%; hazard ratio 0.28; 95% confidence interval 0.10–0.78; p = 0.014). In the group with better HRQoL, all-cause hospitalization was lower, and there was a trend towards lower HF hospitalization (Figure 2) (Table 3).

Table 3. Primary and secondary outcomes during follow-up.

|                                | KCCQ < 75 (n = 72) | KCCQ 75–100 (n = 69) | p-Value |
|--------------------------------|--------------------|----------------------|---------|
| All-cause mortality            | 22 (30.6)          | 10 (14.5)            | 0.014   |
| All-cause hospitalization      | 55 (76.4)          | 43 (62.3)            | 0.017   |
| HF hospitalization             | 30 (41.7)          | 19 (27.5)            | 0.051   |

Data are numbers (percentage). HF: heart failure. The model is adjusted for age, female sex, Barthel index, Clinical Frailty Scale, NT-proBNP value at discharge, New York Heart Association functional class, and Kansas City Cardiomyopathy Questionnaire 75–100.

In patients with a KCCQ-12 measured at one year, there was a statistically significant increase in KCCQ-12. KCCQ-12 went from 71.5 ± 21.5 to 83.1 ± 20.8, p < 0.001, and 69.6% of patients had good-to-excellent HRQoL (Figure 3).
Figure 2. Unadjusted Kaplan–Meier for (A) all-cause death, (B) heart failure hospitalization, and (C) all-cause hospitalization.

Figure 3. Change in KCCQ-12 at one-year follow-up.

Of the 72 patients with impaired HRQoL at baseline, 44 repeated the KCCQ-12 assessment at 12 months. Of those, 15 patients did not improve HRQoL (KCCQ-12 < 75) and 29 patients improved (KCCQ-12 > 75). Baseline characteristics of patients with impaired HRQoL at baseline who did not improve and who improved to a good-to-excellent HRQoL at one-year follow-up are summarized in Tables 4 and 5. A lower proportion of all-cause hospitalization was found in the group with HRQoL improvement, although statistical significance was not reached (62.1% vs. 86.7%, $p = 0.09$).
**Table 4.** Baseline clinical and demographic characteristics of the patients included in the study according to the improvement of KCCQ-12 at one-year follow-up.

|                      | No KCCQ Improvement (n = 15) | KCCQ Improvement (n = 29) | p-Value |
|----------------------|------------------------------|---------------------------|---------|
| Age (years)          | 80.0 ± 4.4                   | 81.9 ± 5.08               | 0.23    |
| Female               | 11 (73.3)                    | 12 (41.4)                 | 0.04    |
| Hypertension         | 14 (93.3)                    | 25 (89.3)                 | 1.00    |
| Diabetes mellitus    | 8 (53.3)                     | 14 (50)                   | 0.84    |
| Dyslipidemia         | 11 (73.3)                    | 19 (65.5)                 | 0.74    |
| Stroke/TIA           | 2 (13.3)                     | 4 (14.8)                  | 1.00    |
| Chronic kidney disease | 11 (73.3)                | 22 (75.9)                 | 1.00    |
| Anemia               | 9 (60)                       | 14 (48.3)                 | 0.46    |
| Peripheral vascular disease | 2 (14.3)                | 4 (13.8)                  | 1.00    |
| Chronic lung disease | 6 (40)                       | 9 (31)                    | 0.55    |
| Cancer               | 2 (13.3)                     | 10 (34.5)                 | 0.17    |
| Myocardial infarction | 2 (13.3)                    | 4 (13.8)                  | 1.00    |
| Coronary percutaneous intervention | 2 (13.3) | 7 (24.1)                  | 0.69    |
| TAVI or Mitraclip    | 1 (7.1)                      | 0 (0)                     | 0.33    |
| Cardiac surgery      | 2 (13.3)                     | 4 (13.8)                  | 0.69    |
| Atrial fibrillation or flutter | 10 (66.7)              | 23 (79.3)                 | 0.47    |
| Moderate to severe valve disease | 4 (28.6)          | 8 (27.6)                  | 1.00    |
| Device therapy:      |                              |                           |         |
| Pacemaker            | 12 (16.7)                    | 10 (14.5)                 | 0.52    |
| CRT or ICD           | 1 (1.4)                      | 4 (5.7)                   | 0.82    |
| Previous history of HF | 7 (46.7)                   | 18 (62.1)                 | 0.33    |
| HF hospitalization the previous year * | 2 (28.6)              | 5 (29.4)                  | 1.00    |
| LVEF (%)             | 62.3 ± 3.9                   | 49.3 ± 13.2               | <0.001  |

Data are number (percentage) or mean ± standard deviation. HF: heart failure; LVEF: left ventricular ejection fraction; TIA: transient ischemic attack; TAVI: transcatheter aortic valve implantation. * Only for patients with a previous history of HF.

**Table 5.** Hospitalization and first appointment characteristics according to the improvement of KCCQ-12 at one-year follow-up.

|                      | No KCCQ Improvement (n = 15) | KCCQ Improvement (n = 29) | p-Value |
|----------------------|------------------------------|---------------------------|---------|
| NT-proBNP at discharge, pg/mL | 1162 (606.6–3579.0)         | 1799.5 (801.9–3562.5)    | 0.44    |
| High-sensitivity T troponin (Hs-TnT) at discharge, ng/L | 31.6 (22.9–44.5)           | 46.9 (22.4–73.0)        | 0.21    |
| eGFR (mL/min) at discharge | 52.9 ± 23.2                  | 46.0 ± 22.1               | 0.36    |
| Frailty (Clinical Frailty Scale) ≥ 4 | 12 (80.0)              | 16 (55.2)                | 0.11    |
| Clinical Frailty Scale | 4.5 ± 1.4                    | 3.9 ± 1.1                 | 0.14    |
| Barthel index         | 76.2 ± 22.0                  | 86.1 ± 13.3               | 0.09    |
| Instrumental activities of daily living (Lawton index) | 4.5 ± 2.3                  | 4.6 ± 2.0                 | 0.82    |
| Pfeiffer Short Portable Mental Status Questionnaire (SPMSQ) | 1 (1–2)                | 1 (1–3)                   | 0.62    |
| NYHA functional class | 2.7 ± 0.7                    | 2.2 ± 0.6                 | 0.053   |
| Intervention geriatrican and cardiologist | 8 (53.3)              | 15 (51.7)                | 0.92    |
| KCCQ-12 at baseline   | 55.1 ± 15.3                  | 52.6 ± 17.5               | 0.64    |

Data are number (percentage), mean ± standard deviation, or median (interquartile range). eGFR: estimated glomerular filtration rate; NT-proBNP: N-terminal prohormone of brain natriuretic peptide; NYHA: New York Heart Association; KCCQ-12: Kansas City Cardiomyopathy Questionnaire-12.
4. Discussion

In our study involving older patients with a recent HF hospitalization, almost half of the patients had impaired HRQoL measured by the KCCQ-12 questionnaire. Surprisingly, baseline characteristics did not allow the identification of patients with worse HRQoL, except for parameters usually associated with aging, such as frailty and functional status measured by Barthel index, NYHA functional class, NT-proBNP, and left ventricular mass index. A good-to-excellent HRQoL was significantly associated with lower one-year all-cause mortality and hospitalization. In patients with HRQoL measured at one year, there was a significant improvement in the KCCQ-12 score.

This study extends prior works describing the association between HRQoL and clinical outcomes. It has already been shown that KCCQ provides prognostic information independent of other clinical data in patients with HF [8,10–15]. However, none of these studies examined the prognostic significance of KCCQ-12 in a prospective elderly cohort with a recent admission for HF. Indeed, our series differs from those previously published in two relevant aspects that should be noted. First, with a mean age of 82.2 years, our population was more than 10 years older than the oldest cohort published to date [33]. Second, the patients’ profiles were rather different from what has been published so far. In fact, the prevalence of HF with a preserved ejection fraction was higher than in previous studies (66.7%), probably concerning the age of the population. Finally, the presence of comorbidities was substantial.

It has been reported that, among a cohort of stable patients with HF, no significant changes were detected by the KCCQ questionnaire at mid-term follow-up. In contrast, large changes were observed among a cohort of patients recovering from admission for decompensated HF [27]. Since the HRQoL assessment in the SENECOR study had a median (interquartile range) of 6 (5–9) after discharge from decompensated HF, our results are in line with previous evidence. Interestingly, patients with impaired HRQoL at baseline who did not have HRQoL improvement at one-year follow-up were more likely to be women. This is consistent with the previous finding that, in a cohort of patients with HF and reduced ejection fraction, women reported significantly worse HRQoL than men, although HRQoL was independently associated with outcome similarly in men and women [34]. On the other hand, patients who did not improve HRQoL also had a higher baseline LVEF than patients who improved. This could be explained by a potential improvement in LVEF over time in the group with a lower baseline LVEF, which could be associated with improvements in HRQoL. However, it could also reflect the several pitfalls that the actual classification of HF based on LVEF values has [35]. Moreover, in our study, a trend towards a lower proportion of all-cause hospitalization was found in the group with HRQoL improvement. Anyway, we must consider a possible selection bias in this analysis due to patients who died or did not repeat the HRQoL assessment at a one-year follow-up.

Better strategies are needed to help physicians efficiently target healthcare resources to HF patients at the highest risk. Our findings suggest that noninvasive risk stratification based on HRQoL measurement by the KCCQ-12 questionnaire can provide prognostic information even in older patients with HF, which could be an essential reference for subsequent treatment decisions when identifying candidates for disease management for whom increased care may reduce hospitalization and prevent death. Future studies are needed to establish whether the assessment of HRQoL in older HF patients with questionnaires such as KCCQ-12 can improve outcomes. It is worth noting that the baseline characteristics did not allow us to identify patients with worse HRQoL. Hence, HRQoL should be assessed in all patients to identify high-risk patients.

Limitations

Since this was a single-center study with a relatively small sample size, our data must be interpreted with caution. Moreover, HRQoL measurements in our study were administered as a part of routine outpatient follow-up visits within a clinical trial. In the setting of a clinical trial, the self-perception of HRQoL may increase regardless of the
intervention due to multiple factors (extra care, more intensive management, optimism, etc.) [36,37]. Whether HRQoL assessments will have similar prognostic value outside this setting remains to be established. Finally, although our results were adjusted for multiple demographic and clinical patient factors, a possibility of residual unmeasured confounding factors cannot be definitively excluded, and our findings need to be validated in a larger-cohort multicenter study.

5. Conclusions

In older patients with a recent hospital admission for HF, good-to-excellent HRQoL was significantly associated with lower one-year all-cause mortality and hospitalization. These data support the assessment of HRQoL in relation to HF in the older population.

Author Contributions: Conceptualization, N.F. and C.R.; methodology, D.L., N.F. and C.R.; validation, D.L., N.F. and C.R.; formal analysis, N.F. and D.L.; investigation, D.L., M.H.-T., N.F., S.R.-B., L.C.B.-T., S.V.-M. and R.O.M.; resources, N.F. and O.V.; data curation, D.L., M.H.-T., N.F., C.R. and N.B.; writing—original draft preparation, D.L.; writing—review and editing, D.L., N.F. and C.R.; supervision, N.F. and C.R.; project administration, N.B.; funding acquisition, N.F. All authors have read and agreed to the published version of the manuscript.

Funding: This research was funded by Fundación MAPFRE, grant Primitivo de la Vega.

Institutional Review Board Statement: The study was conducted in accordance with the Declaration of Helsinki, and approved by the Ethics Committee of Parc de Salut Mar (protocol code number 2017/7653/1, approved on 8 February 2018).

Informed Consent Statement: Informed consent was obtained from all subjects involved in the study.

Data Availability Statement: The data presented in this study are available on request from the corresponding author. The data are not publicly available due to ethical restrictions.

Acknowledgments: We are indebted to all patients and families who agreed to participate in the study, especially those who decided to continue in the middle of the pandemic.

Conflicts of Interest: The authors declare no conflict of interest.

The data presented in this study are available on request from the corresponding author. The data are not publicly available due to ethical restrictions.

Informed Consent Statement: Informed consent was obtained from all subjects involved in the study.

Data Availability Statement: The data presented in this study are available on request from the corresponding author. The data are not publicly available due to ethical restrictions.

Acknowledgments: We are indebted to all patients and families who agreed to participate in the study, especially those who decided to continue in the middle of the pandemic.

Conflicts of Interest: The authors declare no conflict of interest.

The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.

References

1. Farré, N.; Vela, E.; Clíeries, M.; Bustins, M.; Cainzos-Achirica, M.; Enjuanes, C.; Moliner, P.; Ruiz, S.; Verdú-Rotellar, J.M.; Comín-Colet, J. Medical Resource Use and Expenditure in Patients with Chronic Heart Failure: A Population-Based Analysis of 88 195 Patients. Eur. J. Heart Fail. 2016, 18, 1132–1140. [CrossRef]

2. McDonagh, T.A.; Metra, M.; Adamo, M.; Gardiner, R.S.; Baumbach, A.; Böhm, M.; Burri, H.; Butler, J.; Čelutkienė, J.; Chioncel, O.; et al. 2021 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure. Eur. Heart J. 2021, 42, 3599–3726. [CrossRef]

3. Anand, I.S.; Florea, V.G.; Fisher, L. Surrogate End Points in Heart Failure. J. Clin. Med. 2020, 9, 3035. [CrossRef]

4. McMurray, J. Heart Failure: We Need More Trials in Typical Patients. Eur. Heart J. 2000, 21, 699–700. [CrossRef]

5. Cohn, J.; Cleland, J.G.F.; Lubsen, J.; Borer, J.S.; Steg, P.G.; Perelman, M.; Zannad, F. Unconventional End Points in Cardiovascular Clinical Trials: Should We Be Moving Away from Morbidity and Mortality? J. Card. Fail. 2009, 15, 199–205. [CrossRef]

6. Al-Kaade, S.; Hauptman, P.J. Health-Related Quality of Life Measurement in Heart Failure: Challenges for the New Millennium. J. Card. Fail. 2001, 7, 194–201. [CrossRef]

7. Sullivan, M.D.; Levy, W.C.; Russo, J.E.; Crane, B.; Spertus, J.A. Summary Health Status Measures in Advanced Heart Failure: Relationship to Clinical Variables and Outcome. J. Card. Fail. 2007, 13, 560–568. [CrossRef]

8. Heidenreich, P.A.; Spertus, J.A.; Jones, P.G.; Weintraub, W.S.; Rumsfeld, J.S.; Rathore, S.S.; Peterson, E.D.; Masoudi, F.A.; Krumholz, H.M.; Havranek, E.P.; et al. Health Status Identifies Heart Failure Outpatients at Risk for Hospitalization or Death. J. Am. Coll. Cardiol. 2006, 47, 752–756. [CrossRef]

9. Comín-Colet, J.; Garin, O.; Lupón, J.; Manito, N.; Crespo-Leiro, M.G.; Gómez-Bueno, M.; Ferrer, M.; Artigas, R.; Zapata, A.; Elosua, R.; et al. Validation of the Spanish Version of the Kansas City Cardiomyopathy Questionnaire. Rev. Esp. Cardiol. 2011, 64, 51–58. [CrossRef]

10. Kosiborod, M.N.; Jhund, P.S.; Docherty, K.F.; Diez, M.; Petrie, M.C.; Verma, S.; Nicolau, J.C.; Merkely, B.; Kitakaze, M.; DeMets, D.L.; et al. Effects of Dapagliflozin on Symptoms, Function, and Quality of Life in Patients With Heart Failure and Reduced Ejection Fraction: Results From the DAPA-HF Trial. Circulation 2020, 141, 90–99. [CrossRef]
11. Kosiborod, M.; Soto, G.E.; Jones, P.G.; Krumholz, H.M.; Weintraub, W.S.; Deedwania, P.; Spertus, J.A. Identifying Heart Failure Patients at High Risk for Near-Term Cardiovascular Events with Serial Health Status Assessments. *Circulation* 2007, 115, 1975–1981. [CrossRef]

12. Luo, N.; Teng, T.-H.K.; Tay, W.T.; Anand, I.S.; Kraus, W.E.; Liew, H.B.; Ling, L.H.; O’Connor, C.M.; Piña, I.L.; Richards, A.M.; et al. Multinational and Multiethnic Variations in Health-Related Quality of Life in Patients with Chronic Heart Failure. *Am. Heart J.* 2017, 191, 75–81. [CrossRef]

13. Ambrosy, A.P.; Hernandez, A.F.; Armstrong, P.W.; Butler, J.; Dunning, A.; Ezekowitz, J.A.; Felker, G.M.; Greene, S.J.; Kaul, P.; McMurray, J.J.; et al. The Clinical Course of Health Status and Association with Outcomes in Patients Hospitalized for Heart Failure: Insights from ASCEND-HF. *Eur. J. Heart Fail.* 2016, 18, 306–313. [CrossRef]

14. Dunlay, S.M.; Gheorghiade, M.; Reid, K.J.; Allen, L.A.; Chan, P.S.; Hauptman, P.J.; Zannad, F.; Maggioni, A.P.; Swedberg, K.; Konstam, M.A.; et al. Critical Elements of Clinical Follow-up after Hospital Discharge for Heart Failure: Insights from the EVEREST Trial. *Eur. J. Heart Fail.* 2010, 12, 367–374. [CrossRef]

15. Ekman, I.; Chassany, O.; Komajda, M.; Böhmer, J.; Börer, J.S.; Ford, I.; Tavazzi, L.; Swedberg, K. Heart Rate Reduction with Ivabradine and Health Related Quality of Life in Patients with Chronic Heart Failure: Results from the SHIFT Study. *Eur. Heart J.* 2011, 32, 2395–2404. [CrossRef]

16. Lewis, E.F.; Johnson, P.A.; Johnson, W.; Collins, C.; Griffin, L.; Stevenson, L.W. Preferences for Quality of Life or Survival Expressed by Patients with Heart Failure. *J. Heart Lung Transplant.* 2001, 20, 1016–1024. [CrossRef]

17. Herrero-Torrus, M.; Badosa, N.; Roqueta, C.; Ruiz-Bustillo, S.; Solé-González, E.; Belarte-Torner, L.C.; Valdivielso-Moré, S.; Vázquez, O.; Farré, N. Randomized Controlled Trial Comparing a Multidisciplinary Intervention by a Geriatrician and a Cardiologist to Usual Care after a Heart Failure Hospitalization in Older Patients: The SENECOR Study. *J. Clin. Med.* 2022, 11, 1932. [CrossRef]

18. Herrero-Torrus, M.; Badosa, N.; Roqueta, C.; Ruiz-Bustillo, S.; Solé-González, E.; Belarte-Torner, L.C.; Valdivielso-Moré, S.; Vázquez, O.; Farré, N. Randomized Controlled Trial Comparing a Multidisciplinary Intervention by a Geriatrician and a Cardiologist to Usual Care after a Heart Failure Hospitalization in Older Patients: The SENECOR Study. *J. Clin. Med.* 2022, 11, 1932. [CrossRef]

19. Rockwood, K. A Global Clinical Measure of Fitness and Frailty in Elderly People. *Can. Med. Assoc. J.* 2005, 173, 489–495. [CrossRef]

20. Lawton, M.P.; Brody, E.M. Assessment of Older People: Self-Maintaining and Instrumental Activities of Daily Living. *Gerontologist* 1969, 9, 179–186. [CrossRef]

21. Pfeiffer, E. A Short Portable Mental Status Questionnaire for the Assessment of Organic Brain Deficit in Elderly Patients. *J. Am. Geriatr. Soc.* 1975, 23, 433–441. [CrossRef]

22. Spertus, J.A.; Jones, P.G. Development and Validation of a Short Version of the Kansas City Cardiomyopathy Questionnaire. *Circ. Cardiovasc. Qual. Outcomes* 2015, 8, 469–475. [CrossRef]

23. Garcia-Caselles, P.; Miralles, R.; Arellano, M.; Torres, R.M.; Aguilera, A.; Pi-Figueras, M.; Cervera, A.M. Validation of A Modified Short Form of the Gijon’s Social-Familial Evaluation Scale (Sfes): The “Barcelona Sfes Version”, for Patients with Cognitive Impairment. *Arch. Gerontol. Geriatr.* 2004, 38, 201–206. [CrossRef]

24. Martí, D.; Miralles, R.; Llorach, I.; García Palleiro, P.; Esperanza, A.; Guillen, J.; Cervera, A.M. Depressive Mood Disorders in an Inpatient Convalescence Unit: Experience and Validation of a 15-Items Spanish Version of the Yesevagc Geriatric Depression Scale. *Rev. Esp. Geriatr. Gerontol.* 2000, 35, 7–14. [CrossRef]

25. Rubenstein, L.Z.; Harker, J.O.; Salva, A.; Guigoz, Y.; Vellas, B. Screening for Undernutrition in Geriatric Practice: Developing the Short-Form Mini-Nutritional Assessment (MNA-SF). *J. Gerontol. Ser. A Biol. Sci. Med. Sci.* 2001, 56, M366–M372. [CrossRef]

26. Joseph, S.M.; Novak, E.; Arnold, S.V.; Jones, P.G.; Khattak, H.; Platt, A.E.; Dávila-Román, V.G.; Mann, D.L.; Spertus, J.A. Comparable Performance of the Kansas City Cardiomyopathy Questionnaire in Patients With Heart Failure With Preserved and Reduced Ejection Fraction. *Circ. Heart Fail.* 2013, 6, 1139–1146. [CrossRef]

27. Green, C.P.; Porter, C.B.; Bresnahan, D.R.; Spertus, J.A. Development and Evaluation of the Kansas City Cardiomyopathy Questionnaire: A New Health Status Measure for Heart Failure. *J. Am. Coll. Cardiol.* 2000, 35, 1245–1255. [CrossRef]

28. Spertus, J.; Peterson, E.; Conard, M.W.; Heidenreich, P.A.; Krumholz, H.M.; Jones, P.; McCullough, P.A.; Pina, I.; Tooley, J.; Weintraub, W.S.; et al. Monitoring Clinical Changes in Patients with Heart Failure: A Comparison of Methods. *Am. Heart J.* 2005, 150, 707–715. [CrossRef]

29. Hauptman, P.J.; Masoudi, F.A.; Weintraub, W.S.; Pina, I.; Jones, P.G.; Spertus, J.A. Variability in the Clinical Status of Patients with Advanced Heart Failure. *J. Card. Fail.* 2004, 10, 397–402. [CrossRef]

30. Spertus, J.A.; Jones, P.G.; Sandhu, A.T.; Arnold, S.V. Interpreting the Kansas City Cardiomyopathy Questionnaire in Clinical Trials and Clinical Care. *J. Am. Coll. Cardiol.* 2020, 76, 2379–2390. [CrossRef]

31. Harris, P.A.; Taylor, R.; Minor, B.L.; Elliott, V.; Fernandez, M.; O’Neal, L.; McLeod, L.; Delacqua, G.; Delacqua, E.; Kirby, J.; et al. The REDCap Consortium: Building an International Community of Software Platform Partners. *J. Biomed. Inform.* 2019, 95, 103208. [CrossRef]

32. Harris, P.A.; Taylor, R.; Thielle, R.; Payne, J.; Gonzalez, N.; Conde, J.G. Research Electronic Data Capture (REDCap)—A Metadata-Driven Methodology and Workflow Process for Providing Translational Research Informatics Support. *J. Biomed. Inform.* 2009, 42, 377–381. [CrossRef]

33. Pokharel, Y.; Khariton, Y.; Tang, Y.; Nassif, M.E.; Chan, P.S.; Arnold, S.V.; Jones, P.G.; Spertus, J.A. Association of Serial Kansas City Cardiomyopathy Questionnaire Assessments with Death and Hospitalization in Patients With Preserved and Reduced Ejection Fraction. *JAMA Cardiol.* 2017, 2, 1315. [CrossRef]
34. Ravera, A.; Santema, B.T.; Sama, I.E.; Meyer, S.; Lombardi, C.M.; Carubelli, V.; Ferreira, J.P.; Lang, C.C.; Dickstein, K.; Anker, S.D.; et al. Quality of Life in Men and Women with Heart Failure: Association with Outcome, and Comparison between the Kansas City Cardiomyopathy Questionnaire and the EuroQol 5 Dimensions Questionnaire. *Eur. J. Heart Fail.* 2021, 23, 567–577. [CrossRef]

35. Severino, P.; D’Amato, A.; Prosperi, S.; Dei Cas, A.; Mattioli, A.V.; Cevese, A.; Novo, G.; Prat, M.; Pedrinelli, R.; Raddino, R.; et al. Do the Current Guidelines for Heart Failure Diagnosis and Treatment Fit with Clinical Complexity? *J. Clin. Med.* 2022, 11, 857. [CrossRef]

36. Bekelman, D.B.; Plomondon, M.E.; Carey, E.P.; Sullivan, M.D.; Nelson, K.M.; Hattler, B.; McBryde, C.F.; Lehmann, K.G.; Gianola, K.; Heidenreich, P.A.; et al. Primary Results of the Patient-Centered Disease Management (PCDM) for Heart Failure Study. *JAMA Intern. Med.* 2015, 175, 725. [CrossRef]

37. Lewis, E.F. Are Hospitalizations for Heart Failure the Great Equalizer? *JACC Heart Fail.* 2015, 3, 539–541. [CrossRef]